Organigram Holdings Inc. (TSE:OGI) Senior Officer Sells C$30,275.28 in Stock
by Jessica Moore · The Cerbat GemOrganigram Holdings Inc. (TSE:OGI – Get Free Report) Senior Officer Paolo De Luca sold 12,014 shares of Organigram stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of C$2.52, for a total transaction of C$30,275.28.
Paolo De Luca also recently made the following trade(s):
- On Wednesday, September 11th, Paolo De Luca sold 13,835 shares of Organigram stock. The shares were sold at an average price of C$2.54, for a total value of C$35,140.90.
- On Friday, August 16th, Paolo De Luca sold 10,266 shares of Organigram stock. The stock was sold at an average price of C$2.76, for a total value of C$28,334.16.
Organigram Price Performance
Shares of TSE:OGI traded up C$0.02 during midday trading on Tuesday, hitting C$2.60. The company had a trading volume of 229,500 shares, compared to its average volume of 302,154. Organigram Holdings Inc. has a twelve month low of C$1.36 and a twelve month high of C$3.95. The company has a debt-to-equity ratio of 1.13, a current ratio of 6.95 and a quick ratio of 2.62. The business’s 50-day simple moving average is C$2.48 and its 200-day simple moving average is C$2.40. The stock has a market cap of C$282.28 million, a price-to-earnings ratio of -1.03, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13.
Organigram (TSE:OGI – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported C$0.03 EPS for the quarter, beating analysts’ consensus estimates of C($0.07) by C$0.10. The company had revenue of C$41.06 million for the quarter, compared to the consensus estimate of C$39.20 million. Organigram had a negative net margin of 153.80% and a negative return on equity of 54.53%. On average, research analysts predict that Organigram Holdings Inc. will post 0.1632373 earnings per share for the current year.
Analyst Ratings Changes
Separately, Canaccord Genuity Group boosted their price objective on shares of Organigram from C$3.25 to C$3.60 and gave the stock a “speculative buy” rating in a research note on Wednesday, August 14th.
View Our Latest Research Report on OGI
Organigram Company Profile
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Recommended Stories
- Five stocks we like better than Organigram
- How to Invest in Blue Chip Stocks
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- How to Effectively Use the MarketBeat Ratings Screener
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- Profitably Trade Stocks at 52-Week Highs
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?